Pharmaceutical Technology on MSN1d
FDA awards ODD status to Sanofi’s rilzabrutinib for two rare conditions
Sanofi's reversible BTK inhibitor rilzabrutinib has gained the US Food and Drug Administration’s (FDA) orphan drug ...
Healio2d
Rilzabrutinib granted orphan drug designation for IgG4-related disease
The FDA has granted orphan drug designation to rilzabrutinib for IgG4-related disease and warm autoimmune hemolytic anemia, ...
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicinesDesignation granted for warm autoimmune ...
Why Is French Pharma Giant Sanofi Stock Trading Higher On Thursday?
Sanofi's rilzabrutinib receives FDA orphan drug designation for two rare diseases. Clinical studies show meaningful response ...
Medical Dialogues2d
USFDA grants orphan drug designation to Sanofi Rilzabrutinib for two rare diseases
Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to ...
Yahoo Finance2d
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
Rilzabrutinib is currently under regulatory review in the US, EU and China for potential use in immune thrombocytopenia Paris, April 3, 2025. The US Food and Drug Administration (FDA) has granted ...
Sanofi's Rilzabrutinib Gets FDA's Rare-Disease Drug Designation
Sanofi said that its Rilzabrutinib treatment was granted orphan drug designation, which is used in the U.S. by the Food and Drug Administration. The designation is a status assigned to a medicine ...
Pharmabiz1d
US FDA grants orphan drug designation to Sanofi’s rilzabrutinib, an oral, reversible BTK inhibitor for two rare diseases
US FDA grants orphan drug designation to Sanofi’s rilzabrutinib, an oral, reversible BTK inhibitor for two rare diseases: Paris Friday, April 4, 2025, 14:00 Hrs [IST] The US Foo ...
Texas Court Rejects J&J’s Bankruptcy Attempt to End Talc Suits
A bankruptcy court in Texas rejected J&J’s proposed bankruptcy plan to settle claims related to its talc lawsuits for the ...
Zacks Investment Research on MSN2d
SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases
Sanofi SNY announced that the FDA has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, ...
Taiwan News2d
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib is currently under regulatory review in the US, EU and China for potential use in immune ...